Literature DB >> 22982059

Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling.

Aimee J Varewijck1, Michael P Brugts, Jan Frystyk, Jeannette A Goudzwaard, Pieter Uitterlinden, Adriana M Waaijers, Yang Feng, Dimiter S Dimitrov, Steven W J Lamberts, Leo J Hofland, Joseph A M J L Janssen.   

Abstract

BACKGROUND: Only a fraction of circulating insulin-like activity is due to insulin itself. The aim of this study was to determine total serum insulin-like activity mediated via the insulin receptor isoform A (IR-A) and isoform B (IR-B) by using kinase receptor activation (KIRA) assays specific for the IR-A and IR-B.
METHODS: The IR-A and IR-B KIRA assays use human embryonic kidney cells which have been transfected with the human IR-A or IR-B gene and quantify serum-mediated phosphorylation of the IR.
RESULTS: Both IR KIRA assays were sensitive (detection limit 32 pmol/L) and precise (intra- and inter assay CV: <12% and <15%). The EC₅₀s of insulin, IGF-I and IGF-II were 1.4, 11.2 and 6.7 nmol/L for the IR-A KIRA assay, and 1.3, 31.0 and 15.7 nmol/L for the IR-B KIRA assay. The operational range of both assays allowed for determination of total insulin-like activity in human serum. Analysis of serum samples showed that there was a significant positive correlation between serum insulin-like and immunoreactive insulin concentrations (IR-A: r = 0.56, p = 0.01, IR-B: r = 0.68, p = 0.001). Importantly, addition of IGF-I or IGF-II antibodies to human serum samples could substantially decrease the endpoint signal in both KIRA assays.
CONCLUSIONS: We showed that serum IGF-I and IGF-II may substantially contribute to IR signalling. Since IR isoform specific KIRA assays also take into account the contribution of IGFs present in serum on IR signalling, they may help to gain more insight into the roles of IGF mediated IR-A and IR-B activation in health and disease.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22982059      PMCID: PMC6959542          DOI: 10.1016/j.mce.2012.08.021

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  23 in total

1.  A new mathematical model for relative quantification in real-time RT-PCR.

Authors:  M W Pfaffl
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  ANTIBODY-SUPPRESSIBLE AND NONSUPPRESSIBLE INSULIN-LIKE ACTIVITIES IN HUMAN SERUM AND THEIR PHYSIOLOGIC SIGNIFICANCE. AN INSULIN ASSAY WITH ADIPOSE TISSUE OF INCREASED PRECISION AND SPECIFICITY.

Authors:  E R FROESCH; H BUERGI; E B RAMSEIER; P BALLY; A LABHART
Journal:  J Clin Invest       Date:  1963-11       Impact factor: 14.808

3.  Immunoassay of endogenous plasma insulin in man.

Authors:  R S YALOW; S A BERSON
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

4.  The insulin immunoassay after 50 years: a reassessment.

Authors:  Stanley Blumenthal
Journal:  Perspect Biol Med       Date:  2009       Impact factor: 1.416

5.  Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth.

Authors:  Peter M van Koetsveld; Giovanni Vitale; Wouter W de Herder; Richard A Feelders; Katy van der Wansem; Marlijn Waaijers; Casper H J van Eijck; Ernst-Jan M Speel; Ed Croze; Aart-Jan van der Lely; Steven W J Lamberts; Leo J Hofland
Journal:  J Clin Endocrinol Metab       Date:  2006-08-15       Impact factor: 5.958

6.  Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.

Authors:  F Frasca; G Pandini; P Scalia; L Sciacca; R Mineo; A Costantino; I D Goldfine; A Belfiore; R Vigneri
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

7.  Ultrasensitive radioimmunoassay for direct determination of free triiodothyronine concentration in serum.

Authors:  J Weeke; H Orskov
Journal:  Scand J Clin Lab Invest       Date:  1975-05       Impact factor: 1.713

8.  Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells.

Authors:  Giovanni Vitale; Peter M van Koetsveld; Wouter W de Herder; Katy van der Wansem; Joop A M J L Janssen; Annamaria Colao; Gaetano Lombardi; Steven W J Lamberts; Leo J Hofland
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-01-13       Impact factor: 4.310

Review 9.  Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.

Authors:  Antonino Belfiore; Francesco Frasca; Giuseppe Pandini; Laura Sciacca; Riccardo Vigneri
Journal:  Endocr Rev       Date:  2009-09-14       Impact factor: 19.871

10.  Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays.

Authors:  Michael P Brugts; Michael B Ranke; Leo J Hofland; Katy van der Wansem; Karin Weber; Jan Frystyk; Steven W J Lamberts; Joseph A M J L Janssen
Journal:  J Clin Endocrinol Metab       Date:  2008-04-08       Impact factor: 5.958

View more
  6 in total

1.  IFN-β is a potent inhibitor of insulin and insulin like growth factor stimulated proliferation and migration in human pancreatic cancer cells.

Authors:  Stephanie Booy; Casper Hj van Eijck; Joseph Amjl Janssen; Fadime Dogan; Peter M van Koetsveld; Leo J Hofland
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

Review 2.  Insulin analogs and cancer: a note of caution.

Authors:  Joseph A M J L Janssen; Aimee J Varewijck
Journal:  Front Endocrinol (Lausanne)       Date:  2014-05-26       Impact factor: 5.555

Review 3.  IGF-IR Targeted Therapy: Past, Present and Future.

Authors:  Joseph A M J L Janssen; Aimee J Varewijck
Journal:  Front Endocrinol (Lausanne)       Date:  2014-12-23       Impact factor: 5.555

4.  Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling.

Authors:  Aimee J Varewijck; Hannele Yki-Järvinen; Ronald Schmidt; Norbert Tennagels; Joseph A M J L Janssen
Journal:  Diabetes       Date:  2013-04-08       Impact factor: 9.461

5.  Low insulin-like growth factor 1 is associated with low high-density lipoprotein cholesterol and metabolic syndrome in Chinese nondiabetic obese children and adolescents: a cross-sectional study.

Authors:  Shuang Liang; Yanyan Hu; Caihong Liu; Jianhong Qi; Guimei Li
Journal:  Lipids Health Dis       Date:  2016-06-24       Impact factor: 3.876

6.  Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations.

Authors:  Joseph A M J L Janssen; Leo J Hofland; Christian J Strasburger; Elisabeth S R van den Dungen; Mario Thevis
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.